Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AgeX-BAT1

            Therapeutic Area: Endocrinology Product Name: AgeX-BAT1

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Ohio State University

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 10, 2021

            Details:

            The Ohio State University will use AgeX’s brown adipocyte tissue (BAT) cell therapy candidate AgeX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity, metabolic health including glucose metabolism, and cardiac function.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SR-01

            Therapeutic Area: Endocrinology Product Name: SR-01

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Eli Lilly

            Deal Size: $40.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing February 09, 2021

            Details:

            Proceeds from the financing will primarily be used to complete the preclinical testing of SR-01, Seraxis’ lead cell therapy treatment for insulin-dependent diabetes and initiate first-in-human clinical trials.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Stem cell-derived pancreatic islet cell progenitors

            Therapeutic Area: Endocrinology Product Name: PEC-Encap

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: ViaCyte Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement August 05, 2020

            Details:

            Parties have signed an agreement covering the next phase of their ongoing collaboration focused on the development of ViaCyte's Encaptra® Cell Delivery System enabled by proprietary Gore advanced material technologies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: Frazier Healthcare Partners

            Deal Size: $34.6 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing July 27, 2020

            Details:

            Proceeds of the financing will support MBX as it advances its preclinical pipeline of peptide therapeutic candidates directed at clinically validated molecular targets.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PTH(1-34)

            Therapeutic Area: Endocrinology Product Name: PTH(1-34)

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding July 07, 2020

            Details:

            The grant was conferred for the development of a long acting parathyroid hormone – PTH(1-34) – that can be administered once-weekly for treatment of hypo-parathyroidism.